

International PfSPZ Consortium Meeting

The Elm Ballroom rm 208A, University of Maryland,
621 W Lombard Street Baltimore MD 21201

Day 1: Thursday, November 09, 2017 - 12:30-18:00

Time	Subject	Presenter(s)
12:30	Arrival, Registration	
12:30	Coffee	
13:00	Welcome	Peter Billingsley
13:05	Introduction	Chris Plowe, Mike Levine
13:15	Introduction and plans for Phase 3, licensure, and elimination	Stephen Hoffman
Controlled Human Malaria Infections		
13:35	CHMI at University of Maryland	Kirsten Lyke/Matt Laurens
13:50	PfSPZ Challenge (NF54) - Africa (Jongo)	Said Abdalla Jongo/Martin Ondo
14:00	PfSPZ Challenge (NF54) - Kilifi, Kenya	Melissa Kapulu
14:15	PfSPZ Challenge (NF54) - The Gambia	Robert Sauerwein
14:23	PfSPZ Challenge (7G8) - Tübingen	Meral Essen
14:31	PfSPZ Challenge (7G8) - University of Maryland	Matt Laurens
14:39	CHMI moving forward: diluents, strains, and switching to injectable	Tom Richie
14:47	PfSPZ Challenge - A high quality, stable product for benchmarking PfSPZ-based vaccines	Kim Lee Sim
14:55	PvSPZ Challenge: current status	Sumana Chakravarty
15:03	Discussion: unanswered questions and future directions	Moderators: Robert Sauerwein, Benjamin Mordmüller
PfSPZ Vaccine: Stage 2 Clinical Trials		
15:18	General introduction and aims of Stage 2 Trials	Tom Richie
15:26	Warfighter 2	Kirsten Lyke
15:34	MAVACHE	Benjamin Mordmüller
15:42	Mali - MSPZV2	Mahamadou Sissoko /Sara Healy
15:50	Coffee	
16:05	Burkina Faso - BFSPZV1	Sodiomon Sirima
16:13	Tanzania - BSPZV2	Said Jongo
16:21	Kenya - KSPZV1-Part A	Tina Oneko/Reuben Yego
16:29	Kenya - KSPZV1-Part B	Tina Oneko/Tony Sang
16:37	Equatorial Guinea - EGSPZV2	Ally Olotu/Vicente Urbano
16:45	Discussion: regimens and endpoints	Moderators: Ogobara Doumbo, Judy Epstein
Genetically Attenuated Vaccines		
17:00	Outline of PfSPZ-GA strategy	Stephen Hoffman
17:05	PfSPZ-GA1 Vaccine trial in Leiden and Nijmegen	Meta Roestenberg
17:13	PfSPZ-GAP3KO progress and plans in Seattle	Stefan Kappe
17:21	Progress towards a late-liver stage arresting PfSPZ GA Vaccine	Shahid Khan
17:29	Discussion	Moderators: Jim Kublin, Mike Kozar
17:45	Informal Discussion - the View from some of our Sponsors	Annie Mo, Lee Hall, Carl Maas, Mike Kozar, Ken McGhee
18:00	Closing remarks and setting the scene for tomorrow	Stephen Hoffman

19:00 Dinner at the Cazbar: 316 N Charles St, Baltimore, MD 2120

International PfSPZ Consortium Meeting

The Elm Ballroom rm 208A, University of Maryland,
621 W Lombard Street Baltimore MD 21201

Friday, November 10, 2017 - 07:30-16:00

Time	Subject	Presenter
7:30	Breakfast	
	PfSPZ Vaccine Stage 3 CDP: Supporting Phase 2/3 and Pivotal Phase 3 Studies	
8:00	Introduction	Peter Kremsner
8:05	HIV: BSPZV3A (Tanzania)	Said Jongo
8:13	Dose Optimization: EGSPZV3 (Equatorial Guinea)	Steve Manock/Martin Ondo
8:21	Vaccine Efficacy in 1-12 year olds: ESMAVAC (Gabon)	Maxime Agnandji
8:29	Vaccine Efficacy against Pf and Pv in Indonesian soldiers: IPfSPZV1 (Indonesia)	Tom Richie
8:37	Phase 3, Licensure, and Commercialization Manufacturing Including New Vials	Kim Lee Sim
8:45	PfSPZ Vaccine Phase 3 trials and licensure strategy	Tom Richie
8:53	From Phase 2 to BLA/Registration submission: Regulatory Plans	Tooba Murshedkar
9:01	Discussion: From licensure to policy recommendations-what else do we need?	Moderators: Marcel Tanner, Rick Steketee, Brian Greenwood, Sodiomon Sirima, Simon Kariuki, KP Asante
	PfSPZ-CVac Current and Planned Trials	
9:21	Overview of PfSPZ-CVac clinical development plan	Tom Richie
9:26	LMIV, NIAID, NIH - pyrimethamine (USA) - trials 1 and 2	Sara Healy
9:34	Malachite/PfSPZ-CVac 3	Peter Kremsner/Benjamin Mordmüller
9:42	Mali	Mahamadou Thera
9:50	EGSPZV2	Vicente Urbano/Ally Olotu
9:58	Group Health, Seattle – dose escalation, 14 day regimen (USA)	Greg Deye
10:06	Papua Deployment – protection against Pf/Pv (Indonesia)	Tom Richie
10:14	ESMAVAC	Maxime Agnandji
10:22	BSPZV3B	Said Abdallah Jongo
10:30	The ideal partner drug - establishing a research program	Jörg Möhrle
10:38	Discussion	Moderators: Peter Kremsner, Patrick Duffy
10:53	Coffee	
	Pregnancy	
11:08	Introduction	Tom Richie
11:12	Prerequisites for elimination - Pregnancy: the research agenda	Patrick Duffy, Ogo Doumbo, Alisain Dicko
	The Elimination Agenda	
11:22	Introduction	Peter Billingsley
11:27	Current status of malaria control in EG	Julie Niemczura/Carlos Cortes Falla
11:35	Distribution for randomized and implementation approaches: Bioko Island	Eric James
11:43	Defining clusters for demonstration of elimination: Bioko Island	Dave Smith
11:51	From cluster randomized to full implementation: Bioko Island	Marcel Tanner
12:06	Discussion	Moderators: Larry Slutsker, Aaron Samuels, Seth Owusu-Agyei
12:26	Lunch	
	Immunological Studies	
13:14	Introduction	Stephen Hoffman
13:19	Cellular Immunity: immunogenicity, association with protection, mechanism of protection	Phil Swanson
13:27	Cellular immunity: induction	Irfan Zaidi
13:35	Antibodies: immunogenicity, association with protection, mechanism of protection	Sumana Chakravarty
13:43	Antibodies: immunogenicity, association with protection, mechanism of protection	Carlota Dobaño
13:51	Use of proteome arrays for antigen discovery (PfSPZ Vaccine/PfSPZ-CVac)	Angela Yee
13:59	RNAseq correlations during PfSPZ and IMRAS studies	Ken Stuart
	Human mAbs for Understanding Response to PfSPZ-based Vaccines and for Prevention of Pf Malaria	
14:07	Human or humanized mAbs to PfCSP: history and future plans	Stephen Hoffman
14:17	Potent human anti-PfCSP mAbs from malaria naïve volunteers immunized with PfSPZ Vaccine	Neville Kisalu
14:25	Potent and impotent human anti-PfCSP mAbs from malaria naïve volunteers immunized with PfSPZ-CVac	Jean-Philippe Julien
14:33	Potent human anti-PfCSP mAbs from malaria-experienced volunteers immunized with PfSPZ Vaccine	Joshua Tan
14:41	Discussion	Moderators: Maria Yazdanbakhsh, Claudi Daubenberg
14:55	Coffee	
	Research to Improve Manufacturing Capacity	
15:10	Advancing manufacturing: Automating PfSPZ Extraction from Mosquitoes	Sumana Chakravarty
15:20	Advancing manufacturing: Genome editing mosquitoes for increased PfSPZ production	Bill Reid
	Research to Improve Implementation and Vaccine Design	
15:25	Advancing PCR as the primary diagnostic 1	Sean Murphy
15:33	Advancing PCR as the primary diagnostic 2	Chris Plowe
15:41	Advancing PCR by increasing throughput and dramatically reducing costs	Claudia Daubenberg
15:49	Ultrasensitive dipstick as an alternative to PCR	TBD
15:57	Using genomics to advance PfSPZ-based vaccine development	Joana da Silva
16:05	Discussion	Moderators: Preston Church, Sara Healy
	Close-Out Session	
16:05	Consortium priorities	Ogobara Doumbo, Marcel Tanner
16:25	Close out	Stephen Hoffman
16:30	Departure	